Cadrenal Therapeutics (NASDAQ:CVKD) Posts Quarterly Earnings Results, Misses Estimates By $1.03 EPS

Cadrenal Therapeutics (NASDAQ:CVKD) posted its quarterly earnings results on Thursday. The company reported ($2.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.71) by ($1.03), Zacks reports.

Cadrenal Therapeutics Trading Up 9.4 %

Shares of Cadrenal Therapeutics stock opened at $19.09 on Friday. The company has a market capitalization of $34.04 million, a PE ratio of -2.86 and a beta of 1.40. Cadrenal Therapeutics has a 12 month low of $5.40 and a 12 month high of $22.90. The stock’s fifty day simple moving average is $18.31 and its 200 day simple moving average is $15.03.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.